Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Results
  • Discussion
  • Disclosures
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Small ubiquitin-related modifier (SUMO) family proteins are conjugated to the lysine residues of target proteins to regulate various cellular processes. This paper describes a protocol for the detection of retinoblastoma (Rb) protein SUMOylation under endogenous and exogenous conditions in human cells.

Abstract

The post-translational modifications of proteins are critical for the proper regulation of intracellular signal transduction. Among these modifications, small ubiquitin-related modifier (SUMO) is a ubiquitin-like protein that is covalently attached to the lysine residues of a variety of target proteins to regulate cellular processes, such as gene transcription, DNA repair, protein interaction and degradation, subcellular transport, and signal transduction. The most common approach to detecting protein SUMOylation is based on the expression and purification of recombinant tagged proteins in bacteria, allowing for an in vitro biochemical reaction which is simple and suitable for addressing mechanistic questions. However, due to the complexity of the process of SUMOylation in vivo, it is more challenging to detect and analyze protein SUMOylation in cells, especially when under endogenous conditions. A recent study by the authors of this paper revealed that endogenous retinoblastoma (Rb) protein, a tumor suppressor that is vital to the negative regulation of the cell cycle progression, is specifically SUMOylated at the early G1 phase. This paper describes a protocol for the detection and analysis of Rb SUMOylation under both endogenous and exogenous conditions in human cells. This protocol is appropriate for the phenotypical and functional investigation of the SUMO-modification of Rb, as well as many other SUMO-targeted proteins, in human cells.

Introduction

The accurate control of cell cycle progression in eukaryotic cells is based on a tight regulatory network, which ensures that particular events take place in an ordered manner1,2. One of the key players in this network is the retinoblastoma (Rb) protein, the first cloned tumor suppressor1,3. The Rb protein is thought to be a negative regulator of cell cycle progression, especially for the G0/G1 to S phase transition, and tumor growth4,5. Failure of Rb function either directly leads to the most common intraocular malignancy in children, retinoblastoma, or contributes to the development of many other types of cancer5. Moreover, Rb is involved in many cellular pathways including cell differentiation, chromatin remodeling, and mitochondria-mediated apoptosis3,6,7.

Post-translational modifications play a pivotal role in the regulation of RB function8,9. Phosphorylation is one such modification, and it usually leads to Rb inactivation. In quiescent G0 cells, Rb is active with a low phosphorylation level. As cells progress through G0/G1 phase, Rb is sequentially hyper-phosphorylated by a series of cyclin-dependent protein kinases (CDKs) and cyclins, such as cyclin E/CDK2 and cyclin D/CDK4/6, which inactivate Rb and eliminate its ability to repress cell-cycle related gene expression4,10. Rb could also be modified by small ubiquitin-related modifier (SUMO)11,12,13.

SUMO is a ubiquitin-like protein that is covalently attached to a variety of target proteins. It is crucial for diverse cellular processes, including cell cycle regulation, transcription, protein cellular localization and degradation, transport, and DNA repair14,15,16,17,18. The SUMO conjugation pathway consists of the dimeric SUMO E1 activating enzyme SAE1/UBA2, the single E2 conjugating enzyme Ubc9, multiple E3 ligases, and SUMO-specific proteases. Generally, nascent SUMO proteins must be proteolytically processed to generate the mature form. The mature SUMO is activated by the E1 heterodimer and then transferred to the E2 enzyme Ubc9. Finally, the C-terminal glycine of SUMO is covalently conjugated to the target lysine of a substrate, and this process is usually facilitated by E3 ligases. The SUMO protein can be removed from the modified substrate by specific proteases. A previous study by the authors of this paper revealed that SUMOylation of Rb increases its binding to CDK2, leading to hyper-phosphorylation at the early G1 phase, a process which is necessary for cell cycle progression13. We also demonstrated that the loss of Rb SUMOylation causes a decreased cell proliferation. Moreover, it was recently demonstrated that the SUMOylation of Rb protects the Rb protein from proteasomal turnover, thus increasing the level of Rb protein in cells19. Therefore, SUMOylation plays an important role in Rb function in various cellular processes. To further study the functional consequence and physiological relevance of Rb SUMOylation, it is important to develop an effective method to analyze the SUMO status of Rb in human cells or patient tissues.

SUMOylation is a reversible, highly dynamic process. Thus, it is usually difficult to detect the SUMO-modified proteins under completely endogenous conditions. This paper presents a method to detect endogenous Rb SUMOylation. Furthermore, it shows how to detect exogenous Rb SUMOylation of both wild-type Rb and its SUMO-deficient mutation11. In particular, Jacobs et al. described a method to increase the SUMO modification of a given substrate specifically by Ubc9 fusion-directed SUMOylation (UFDS)20. Based on this method, this protocol describes how to analyze the forced SUMOylation of Rb and its functional consequences. Given that hundreds of SUMO substrates have been described previously and more putative SUMO substrates have been identified from many proteomic-based assays, this protocol can be applied to analyze the SUMO-modification of these proteins in human cells.

Protocol

1. Detection of Endogenous Rb SUMOylation at the Early G1 Phase

  1. Cell culture and cell cycle synchronization.
    1. Maintain HEK293 cells in growth medium containing Dulbecco's Modified Eagle Medium (DMEM) supplemented with 1% Pen-Strep and 10% fetal bovine serum (FBS) at 37 °C and 5% CO2 in an incubator.
    2. Synchronize the HEK293 cells at the G0 phase.
      1. Count the HEK293 cells using a hemocytometer and seed ~1.5 x 107 cells in a 15 cm dish with 25ml growth medium for 24 h before treatment. After reaching a confluence of 70% - 80%, aspirate the medium and wash the cells twice with 5 mL prewarmed phosphate-buffered saline (PBS).
      2. Add 25 mL DMEM containing 1% Penicillin-Streptomycin and incubate the cells at 37 °C for 72 h. Wash the cells off the plate using 3 mL ice-cold PBS. Transfer the cells into a new 5 mL tube.
      3. Subject a small portion of cells to cell cycle analysis by flow cytometry (step 1.2); collecting the remaining majority of the cells by centrifugation at 200 x g for 5 min at room temperature, and then store them in an ultra-lower temperature freezer until analysis of Rb SUMOylation.
    3. To obtain G1-phase cells, at the end of the G0 synchronization process, remove the DMEM and add back fresh growth medium, thus allowing the HEK293 cells to re-enter the cell cycle. Then, collect the cells at different G1 phases (early G1: 30 min; G1: 2h) for cell cycle analysis and further SUMO assay.
    4. Synchronize the HEK293 cells at the S phase using the double-thymidine block method.
      1. Grow HEK293 cells to a confluency of 50% and wash cells with prewarmed PBS. Then add growth medium supplemented with 2.5 mM thymidine for 18 h (first block).
      2. Remove the thymidine-containing medium, and then wash the cells twice with prewarmed PBS. Add fresh growth medium for 14 h to release the cells.
      3. Discard the medium with a pipette and add growth medium supplemented with 2.5 mM thymidine for another 18 h (second block) before conducting an analysis of the cell cycle and Rb SUMOylation.
    5. For the G2/M synchronization, plate ~1.5 × 107 HEK293 cells to a 15 cm dish with 25 mL growth medium for 24 h. Then add nocodazole to the medium until a final concentration of 400 ng/mL is obtained. Finally, incubate the cells for 16 h before conducting the analysis of the cell cycle and Rb SUMOylation.
  2. Cell cycle analysis by flow cytometry.
    1. Re-suspend the synchronized HEK293 in PBS, and then fix the cell suspension using ice-cold 70% ethanol for 2 h at 4 °C. Note that to minimize cell clustering, add the cell suspension dropwise to the ice-cold 100% ethanol to obtain a final concentration of 70% ethanol while gently vortexing.
    2. Centrifuge the cells for 5 min at 500 x g, then carefully discard the supernatant and wash the cells twice with PBS. Repeat the centrifuge step.
    3. Add 500 µL PBS containing 50 µg/mL nucleic acid stain propidium iodide, 0.1% Triton X-100 and 1 µg/mL RNase A to the cells and mix well. Incubate the cells for 15 min at 37 °C.
    4. Store the samples at 4 °C until analysis by flow cytometry.
  3. Immunoprecipitation of endogenous Rb protein.
    1. Prepare the HEK293 cell lysates.
      1. Lyse the synchronized HEK293 cells by gently re-suspending them in 1 mL of ice-cold radio-immunoprecipitation assay (RIPA) lysis buffer (Table 1) containing freshly added 20 mM N-Ethylmaleimide, an isopeptidase inhibitor that could block SUMO proteases and stabilize SUMO conjugates.
      2. Further homogenize the cells on ice by Dounce homogenization, sonication or simply passing through 10 times through a 21 G needle attached on a 2 mL syringe. Then, incubate the cells on ice for 5 min.
        NOTE: The anionic detergent sodium dodecyl sulfate (SDS) in the RIPA buffer is crucial for the later determination of the Rb-SUMO, as it could eliminate the unspecific SUMO signal that is derived from the non-covalent interaction between the Rb protein and other non-Rb SUMO-species.
    2. Centrifuge the cell lysates at 18,000 x g for 30 min at 4 °C. Transfer the supernatants to new 1.5 mL micro-centrifuge tubes.
      NOTE: The protocol can be paused here. The proteins can be stored at -80 °C for at least 6 months.
    3. To prepare the input control of each sample for the later Western blot, save a small portion of the above-described supernatant to a new tube and store at -80 °C.
    4. To the above supernatants, add 1 µg of non-specific mouse immunoglobulin G (IgG) of the same species and isotype as the monoclonal Rb antibody, and 20 µL of 50% protein A/G-sepharose slurry. Then, incubate for 1 h at 4 °C with gentle rotation.
    5. Centrifuge the samples at 3,000 x g for 3 min at 4 °C. Carefully collect the supernatants without disturbing the beads, and transfer them to new 1.5 mL micro-centrifuge tubes. To each of the samples, add 5 µL Rb primary antibody and 40 µL of 50% protein A/G-sepharose slurry. Then, incubate overnight at 4 °C with gentle rotation.
    6. Collect the beads by centrifugation at 3,000 x g for 3 min at 4 °C, and carefully remove the supernatant by pipetting. Note that in order to avoid bead loss, do not aspirate the beads dry.
    7. Wash the beads four times with 1 mL of the RIPA buffer. Each time, mix the tubes well by rotation them at 4 °C for 15 min. Collect the beads by low speed centrifugation at 3,000 x g for 3 min at 4 °C and then discard the supernatants.
    8. After removing supernatants from the final wash, re-suspend the beads in 30 µL 1x sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer (Table 1) and mix well.
      1. Incubate the tubes at 100 °C in a heat block for 10 min. Centrifuge the samples at 12,000 x g for 1 min to pellet the beads. Carefully collect the supernatants without disturbing the beads, and transfer them to 1.5 mL micro-centrifuge tubes.
    9. Analyze the samples by 4% - 20% gradient SDS-PAGE gel and Western blot or store them at -20 °C for later use.

2. Analysis of 6XHis-tagged Exogenous Rb SUMOylation in Human Cells

  1. Cell culture and transfection.
    1. Seed ~6 × 106 HEK293 cells in a 10 cm dish and incubate for 24 h in growth medium under normal cell culture conditions to acquire 75%-85% confluent cells. Before transfection, remove the growth medium and add 6 mL of prewarmed reduced serum medium (see Table of Materials) and then place the dishes back into the incubator.
    2. For the Rb constitutive SUMOylation assay, add 15 µg each of the 6XHis-tagged Rb-Ubc9-WT, Rb-Ubc9-C93S, Ubc9-WT and Ubc9-C93S plasmids in 500 µL reduced serum medium in 1.5 mL micro-centrifuge tubes, respectively.
      1. To analyze the SUMO-conjugation of wild type Rb and its SUMOylation-defective mutant, mix 10 µg of either 6XHis-tagged Rb-WT or Rb-K720R plasmid together with GFP-SUMO1 (10 µg) in 500 µL reduced serum medium in 1.5 mL micro-centrifuge tubes13.
    3. Meanwhile, in a separate tube, mix 50 µL transfection reagent (see Table of Materials) in 500 µL reduced serum medium, and incubate at room temperature for 5 min.
    4. Fully combine the two separate tubes described above, and incubate at room temperature for 15 min. Add the transfection reagent/plasmid complexes to the cells and continue to culture for 8 h at 5% CO2 and 37 °C.
    5. Replace reduced serum medium with growth medium, and incubate the cells under normal culture conditions for 48 h after transfection.
  2. Nickel affinity pull down of the 6XHis-tagged Rb protein.
    1. Lyse the transfected HEK293 cells and extract the total proteins as described Section 1.3.1.
    2. Centrifuge the cell lysates at 18,000 x g for 30 min at 4 °C. Carefully collect the supernatants and transfer them to clean tubes.
      NOTE: The protein can be frozen at this point for more than 6 months at -80 °C.
    3. To prepare the input control of each sample for the later Western blot, save a small portion of the supernatants described above to a new tube and store at -80 °C.
    4. Wash 25 µL of 50% nickel nitrilotriacetic acid (Ni-NTA) agarose beads with RIPA buffer twice in a 1.5 mL micro-centrifuge tube for each sample. Collect the beads by centrifugation at 3,000 x g for 3 min at 4 °C.
    5. Add 1 M imidazole to each sample to obtain a final concentration of 10 mM. Then, add each sample to the tube containing the prepared Ni-NTA agarose beads.
    6. Incubate the beads and the lysates for 2 h at 4 °C with gentle rotation. Spin the beads at 3,000 x g for 3 min at 4 °C, and carefully remove the supernatants by pipetting. To avoid bead loss, do not aspirate the beads dry.
    7. Wash the beads with 1 mL of wash buffer containing 20 mM imidazole (Table 1). Each time, mix the tubes well by rotation at 4 °C for 15 min. Collect the beads by spinning at 3,000 x g for 3 min at 4 °C, and discard the supernatants.
    8. After the final wash, add 30 µL of elution buffer containing 250 mM imidazole (Table 1) to each sample and flick to mix. Then, incubate for 20 min at 4 °C to elute the proteins.
    9. Mix each sample with 6× SDS-PAGE loading buffer (Table 1). Then, incubate the tubes at 100 °C in a heat block for 10 min.
    10. Centrifuge at 12,000 x g for 1 min to pellet the beads. Carefully collect the supernatants without disturbing the beads, and transfer the samples to 1.5 ml micro-centrifuge tubes. The samples can be analyzed by Western blot or stored at -20 °C for later use.

3. Western Blot

  1. Load the immunoprecipitation or pull down samples obtained from the previous steps onto 4-20% gradient SDS-PAGE gels. Conduct electrophoresis at 120 V for 90 min to separate the proteins.
  2. Transfer the proteins from the gel to a polyvinylidene difluoride (PVDF) membrane by electroblotting at 300 mA for 90 min at 4 °C using the tank transfer method. Block the PVDF membrane in block buffer containing 5% nonfat milk (Table 1) for 1 h at room temperature.
  3. Incubate the membrane with primary antibody in antibody dilution buffer containing 3% bovine serum albumin (BSA) (Table 1) overnight at 4 °C. For primary antibodies, use a working concentration of 0.5 µg/mL (anti-SUMO1 antibody), or a dilution of 1:2000 (anti-Rb and anti-Tubulin antibodies), or 1:5,000 (anti-GFP and anti-His antibody).
  4. Wash the membrane 3x for 10 min each time using 1x tris-buffered saline with Tween (TBST) buffer (Table 1). Incubate the membrane with species specific Horseradish Peroxidase (HRP)-conjugated secondary antibodies diluted 1:5,000 in block buffer containing 5% nonfat milk (Table 1). Wash the membrane 3x for 10 min each time using 1x TBST buffer.
  5. Incubate the membrane with enhanced chemiluminescence (ECL) working solution. Cover the membrane with plastic wrap and expose it to X-ray film depending on the strength of signal.

Results

To detect endogenous Rb SUMOylation during cell cycle progression, this study first synchronized HEK293 cells at five different stages of the cell cycle (G0, early G1, G1, S, and G2/M) as described in the protocol section of this paper. The quality of synchronization was confirmed by using the nucleic acid stain with propidium iodide followed by flow cytometry analysis (Figure 1). Next, the cells were collected and lysed by denaturing RIPA buffer.The SUMO pro...

Discussion

This paper describes a protocol to detect and analyze the endogenous SUMOylation of Rb in human cells. As this method is specifically focused on the endogenous Rb protein without any alternation of global SUMO-related signal, it is an important tool for investigating Rb-SUMO modification under completely natural physiologic circumstances.

To achieve this aim, it is important to keep in mind that: 1) although SUMO comprises four isoforms (SUMO1-4, each encoded by different genes)in comparison t...

Disclosures

The authors have nothing to disclose.

Acknowledgements

This study was supported by grants from the Science and Technology Commission of Shanghai (Grant No. 14411961800) and National Natural Science Foundation of China (Grant No. 81300805).

Materials

NameCompanyCatalog NumberComments
Dulbecco's Modified Eagle Medium (DMEM)Thermo Fisher Scientific11995065
Opti-MEM Thermo Fisher Scientific31985070
Fetal Bovine Serum (FBS)Thermo Fisher Scientific26140079
Penicillin-StreptomycinThermo Fisher Scientific15140122
Phosphate-buffered Saline (PBS)Thermo Fisher Scientific10010023
Trypsin-EDTAThermo Fisher Scientific25200056
ThymidineSigmaT9250
NocodazoleSigmaM1404
propidium iodideThermo Fisher ScientificP3566
Triton X-100 AMRESCO694
RNase A Thermo Fisher ScientificEN0531
N-EthylmaleimideSigmaE3876 
Sodium Dodecyl Sulfate (SDS)AMRESCOM107
Nonidet P-40 Substitute (NP-40)AMRESCOM158
protease inhibitorRoche5892970001
Mouse Immunoglobulin G (IgG)Santa Cruz Biotechnologysc-2025
Rb antibodyCell Signaling Technology#9309
Protein A/G-Sepharose BeadsSanta Cruz Biotechnologysc-2003
Lipofectamine-2000 Thermo Fisher Scientific11668019
Nickel Nitrilotriacetic Acid (Ni-NTA) Agarose BeadsQiagen30230
ImidazoleSigmaI0250
4%-20% Gradient SDS-PAGE GelBIO-RAD4561096
Polyvinylidene Difluoride (PVDF) MembraneMilliporeIPVH00010
Tween-20AMRESCOM147
Tubulin antibodyAbmartM30109
SUMO1 antibodyThermo Fisher Scientific33-2044
GFP antibodyAbmartM20004
Horseradish Peroxidase (HRP) secondary antibodyJackson ImmunoResearch Laboratories715-035-150
enhanced chemiluminescence (ECL) KitThermo Fisher Scientific32106

References

  1. Bertoli, C., Skotheim, J. M., de Bruin, R. A. Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol. 14 (8), 518-528 (2013).
  2. Massague, J. G1 cell-cycle control and cancer. Nature. 432 (7015), 298-306 (2004).
  3. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell. 81 (3), 323-330 (1995).
  4. Giacinti, C., Giordano, A. RB and cell cycle progression. Oncogene. 25 (38), 5220-5227 (2006).
  5. Burkhart, D. L., Sage, J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 8 (9), 671-682 (2008).
  6. Ferreira, R., Naguibneva, I., Pritchard, L. L., Ait-Si-Ali, S., Harel-Bellan, A. The Rb/chromatin connection and epigenetic control: opinion. Oncogene. 20 (24), 3128-3133 (2001).
  7. Hilgendorf, K. I., et al. The retinoblastoma protein induces apoptosis directly at the mitochondria. Genes Dev. 27 (9), 1003-1015 (2013).
  8. Munro, S., Carr, S. M., La Thangue, N. B. Diversity within the pRb pathway: is there a code of conduct. Oncogene. 31 (40), 4343-4352 (2012).
  9. Macdonald, J. I., Dick, F. A. Posttranslational modifications of the retinoblastoma tumor suppressor protein as determinants of function. Genes Cancer. 3 (11-12), 619-633 (2012).
  10. Ezhevsky, S. A., et al. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. Proc Natl Acad Sci U S A. 94 (20), 10699-10704 (1997).
  11. Ledl, A., Schmidt, D., Muller, S. Viral oncoproteins E1A and E7 and cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor suppressor. Oncogene. 24 (23), 3810-3818 (2005).
  12. Li, T., et al. Expression of SUMO-2/3 induced senescence through p53- and pRB-mediated pathways. J Biol Chem. 281 (47), 36221-36227 (2006).
  13. Meng, F., Qian, J., Yue, H., Li, X., Xue, K. SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase. Cell Cycle. 15 (13), 1724-1732 (2016).
  14. Geiss-Friedlander, R., Melchior, F. Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol. 8 (12), 947-956 (2007).
  15. Flotho, A., Melchior, F. Sumoylation: a regulatory protein modification in health and disease. Annu Rev Biochem. 82, 357-385 (2013).
  16. Eifler, K., Vertegaal, A. C. SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer. Trends Biochem Sci. 40 (12), 779-793 (2015).
  17. Wilkinson, K. A., Henley, J. M. Mechanisms, regulation and consequences of protein SUMOylation. Biochem J. 428 (2), 133-145 (2010).
  18. Gill, G. SUMO and ubiquitin in the nucleus: different functions, similar mechanisms. Genes Dev. 18 (17), 2046-2059 (2004).
  19. Sharma, P., Kuehn, M. R. SENP1-modulated sumoylation regulates retinoblastoma protein (RB) and Lamin A/C interaction and stabilization. Oncogene. 35 (50), 6429-6438 (2016).
  20. Jakobs, A., et al. Ubc9 fusion-directed SUMOylation (UFDS): a method to analyze function of protein SUMOylation. Nat Methods. 4 (3), 245-250 (2007).
  21. Gareau, J. R., Lima, C. D. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol. 11 (12), 861-871 (2010).
  22. Bernier-Villamor, V., Sampson, D. A., Matunis, M. J., Lima, C. D. Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. Cell. 108 (3), 345-356 (2002).
  23. Saitoh, H., Hinchey, J. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem. 275 (9), 6252-6258 (2000).
  24. Ayaydin, F., Dasso, M. Distinct in vivo dynamics of vertebrate SUMO paralogues. Mol Biol Cell. 15 (12), 5208-5218 (2004).

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Explore More Articles

Keywords Rb Protein SUMOylationIn Vivo DetectionHuman CellsSUMO ConjugationCell SynchronizationG1 PhaseS PhaseG2 M PhaseHEK293 CellsCell Cycle AnalysisFlow CytometryRIPA Lysis

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved